RxDoctor Payments Data

Charles Oshaughnessy, MD

Interventional Cardiology · Elyria, OHNPI 1831178003

Payments from drug & device makers

$39,665in general payments, 2019–2025

Across 125 payments — averaging $317.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$18K
  • AstraZeneca$11K
  • Medtronic$9K
  • Abbott$357
  • Novartis$242
  • Abiomed$187
  • plus $489 from 11 others

What the payments were for

  • Speaking & faculty fees$10,55077%
  • Travel & lodging$9287%
  • Food & beverage$2,30517%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,665 in reported general payments places this provider in the 70th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$207,384
Medicare patients
903
Services billed
1,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban541$663,885
EntrestoSacubitril/Valsartan197$258,977
XareltoRivaroxaban134$148,703
Repatha SureclickEvolocumab109$123,430
JardianceEmpagliflozin41$60,846
BrilintaTicagrelor35$28,952
Atorvastatin Calcium1,716$19,120
Ranolazine ErRanolazine152$17,014
ClopidogrelClopidogrel Bisulfate1,025$12,507
Metoprolol Succinate750$10,671
Potassium Chloride326$8,398
Nitroglycerin549$7,714
Isosorbide Mononitrate ErIsosorbide Mononitrate371$6,163
Metoprolol Tartrate941$5,658
Losartan Potassium570$5,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$663,885541 claims
NovartisEntresto$242$258,977197 claims
Boehringer IngelheimJardiance$13$60,84641 claims
AstraZenecaBrilinta$10,949$28,95235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Elyria

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →